東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Design and synthesis of etoposide-re...

Xiao, Zhiyan.

FindBook

Google Book

Amazon

博客來

Design and synthesis of etoposide-related topoisomerase II inhibitors by conventional and computational approaches.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Design and synthesis of etoposide-related topoisomerase II inhibitors by conventional and computational approaches./
作者:	Xiao, Zhiyan.
面頁冊數:	141 p.
附註:	Source: Dissertation Abstracts International, Volume: 64-08, Section: B, page: 3769.
Contained By:	Dissertation Abstracts International64-08B.
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3100362

Design and synthesis of etoposide-related topoisomerase II inhibitors by conventional and computational approaches.
Xiao, Zhiyan.

Design and synthesis of etoposide-related topoisomerase II inhibitors by conventional and computational approaches. - 141 p.

Source: Dissertation Abstracts International, Volume: 64-08, Section: B, page: 3769.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2003.

Etoposide (1) and teniposide (2) are DNA topoisomerase II (topo II) inhibitors that have been used in front-line cancer chemotherapy since the 1980s. Problems associated with 1 and 2 include acquired drug-resistance, poor water-solubility, and metabolic inactivation. To circumvent the aforementioned problems, three series of analogs were designed, synthesized, and evaluated for activity in causing cellular protein-linked DNA breakage as well as cytotoxicity against KB and 1-resistant KB/7d cells. Molecular modeling studies were incorporated to formulate useful structure-activity relationships (SAR) and guide rational optimization of this compound class.Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Design and synthesis of etoposide-related topoisomerase II inhibitors by conventional and computational approaches.
LDR:03144nmm 2200301 4500 001 1860511
005 20041028080312.5
008 130614s2003 eng d
035 $a (UnM)AAI3100362
035 $a AAI3100362
040 $a UnM $c UnM
100 1 $a Xiao, Zhiyan. $3 1948143
245 1 0 $a Design and synthesis of etoposide-related topoisomerase II inhibitors by conventional and computational approaches.
300 $a 141 p.
500 $a Source: Dissertation Abstracts International, Volume: 64-08, Section: B, page: 3769.
500 $a Director: Kuo-Hsiung Lee.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2003.
520 $a Etoposide (1) and teniposide (2) are DNA topoisomerase II (topo II) inhibitors that have been used in front-line cancer chemotherapy since the 1980s. Problems associated with 1 and 2 include acquired drug-resistance, poor water-solubility, and metabolic inactivation. To circumvent the aforementioned problems, three series of analogs were designed, synthesized, and evaluated for activity in causing cellular protein-linked DNA breakage as well as cytotoxicity against KB and 1-resistant KB/7d cells. Molecular modeling studies were incorporated to formulate useful structure-activity relationships (SAR) and guide rational optimization of this compound class.
520 $a Several quantitative SAR (QSAR) methods, including comparative molecular field analysis (CoMFA), q2 Guided Region Selection (q2-GRS), and k Nearest Neighbor (kNN) QSAR, were used to generate QSAR models for 157 epipodophyllotoxins. Robust models with consistently high q2 and predictive R2 values were provided by the kNN-QSAR technique. Pharmacophore modeling of four diverse topo II inhibitors was also attempted with the HipHop module implemented in Catalyst. These models, in combination with prior SAR and conventional drug design approaches, directed the synthetic efforts.
520 $a C4 modification using different linkages (p-carbonyl anilino, p-amino anilino, amino, and carbonyl) extended with protected amino acids was intended to optimize activity and modulate water-solubility simultaneously. Eight compounds (6--11, 15--16) induced more protein-linked DNA breaks than 1, with two of them (9 and 16) superior to GL 331, a novel 4beta-arylamino analog currently in phase II clinical trials. The preliminary metabolism and toxicity studies of selected compounds encourage further development and analog synthesis following this molecular design.
520 $a C4' esterification was introduced to improve the water-solubility of this compound class. The esterified derivatives retained the superior activity and drug-resistance profiles of the parent compounds.
520 $a D-ring enol ether variation was designed to eliminate the C2 epimerization and hydrolysis metabolic pathways. Rudimentary chemistry of this modification was explored.
590 $a School code: 0153.
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0572
710 2 0 $a The University of North Carolina at Chapel Hill. $3 1017449
773 0 $t Dissertation Abstracts International $g 64-08B.
790 1 0 $a Lee, Kuo-Hsiung, $e advisor
790 $a 0153
791 $a Ph.D.
792 $a 2003
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3100362